19:54 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

FDA lifts hold on Aptose blood cancer candidate

Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) said FDA lifted a two-and-a-half year clinical hold on a Phase Ib trial evaluating IV APTO-253 in patients with hematologic malignancies. In 2015, FDA placed a hold on the open-label,...
17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it received a response from FDA regarding a clinical hold the agency placed last November on its open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. According to Aptose,...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

Aptose said it submitted a formal response to FDA’s requests following a November 2015 clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The company had voluntarily...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-25 (IL-25; IL-17E)

Infectious disease INDICATION: Clostridium Patient sample and mouse studies suggest IL-25 could help treat Clostridium difficile infection (CDI). In patient intestinal tissue samples, levels of IL-25 protein were lower than in samples from healthy volunteers....
07:00 , Jun 13, 2016 |  BC Week In Review  |  Company News

CrystalGenomics, Aptose Biosciences deal

CrystalGenomics granted Aptose an exclusive option to license rights to CG026806 outside of China and Korea. CrystalGenomics will receive an upfront payment of $1 million and is eligible for a $2 million option exercise payment...
02:43 , Jun 9, 2016 |  BC Extra  |  Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk) ,...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

APTO-253: Phase Ib hold

FDA placed a clinical hold on an open-label, dose-escalation, U.S. Phase Ib trial of IV APTO-253 in about 45-60 patients. The hold follows a voluntary suspension of dosing and preliminary review that found concerns regarding...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Aptose Biosciences, Laxai Avanti Life Sciences deal

Aptose partnered with CRO Laxai Avanti Life Sciences to develop next-generation epigenetic-based therapies. Laxai will optimize multiple clinical candidates from Aptose, including candidates to treat hematologic malignancies and solid tumors that Aptose licensed from H....
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

H. Lee Moffitt Cancer Center, Aptose Biosciences deal

Moffitt Cancer Center granted Aptose exclusive, worldwide rights to develop and commercialize preclinical, small molecule dual BET bromodomain protein and kinase inhibitors to treat hematologic malignancies and solid tumors. Aptose expects to select lead clinical...